Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free RVMD Stock Alerts

Revolution Medicines (RVMD) Financials

Revolution Medicines logo
$144.15 +2.34 (+1.65%)
Closing price 04:00 PM Eastern
Extended Trading
$143.65 -0.50 (-0.35%)
As of 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Revolution Medicines

Annual Income Statements for Revolution Medicines

This table shows Revolution Medicines' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -49 -62 -110 -187 -249 -436 -600 -1,131
Consolidated Net Income / (Loss)		 -42 -48 -108 -187 -249 -436 -600 -1,131
Net Income / (Loss) Continuing Operations		 -42 -48 -108 -187 -249 -436 -600 -1,131
Total Pre-Tax Income 		-42 -52 -109 -187 -249 -440 -601 -1,131
Total Operating Income		 -40 -54 -111 -188 -258 -487 -690 -1,182
Total Gross Profit		 20 50 43 29 35 12 0.00 0.00
Total Revenue		 20 50 43 29 35 12 0.00 0.00
Operating Revenue		 20 50 43 29 35 12 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 60 104 154 217 294 499 690 1,182
Selling, General & Admin Expense		 9.41 12 21 30 41 76 97 195
Research & Development Expense		 51 92 132 187 253 423 592 987
Total Other Income / (Expense), net		 -1.46 2.08 2.17 0.92 9.15 47 89 51
Interest Expense		 0.12 0.11 0.07 - - 0.00 0.00 24
Interest & Investment Income		 0.78 2.19 2.24 0.93 9.15 47 87 91
Other Income / (Expense), net		 -2.12 - - -0.01 0.00 -0.19 -2.53 -15
Income Tax Expense		 0.00 -4.37 -0.37 0.00 -0.42 -3.52 -0.75 0.00
Basic Earnings per Share		 ($21.24) ($22.33) ($2.01) ($2.57) ($3.08) ($3.86) ($3.58) ($5.95)
Weighted Average Basic Shares Outstanding		 2.30M 2.77M 54.87M 72.81M 80.63M 113.15M 167.74M 190.13M
Diluted Earnings per Share		 ($21.24) ($22.33) ($2.01) ($2.57) ($3.08) ($3.86) ($3.58) ($5.95)
Weighted Average Diluted Shares Outstanding		 2.30M 2.77M 54.87M 72.81M 80.63M 113.15M 167.74M 190.13M
Weighted Average Basic & Diluted Shares Outstanding		 2.30M 2.77M 54.87M 72.81M 90.49M 164.69M 185.91M 198.17M

Quarterly Income Statements for Revolution Medicines

This table shows Revolution Medicines' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -108 -162 -116 -133 -156 -195 -213 -248 -305 -365 -454
Consolidated Net Income / (Loss)		 -108 -162 -116 -133 -156 -195 -213 -248 -305 -365 -454
Net Income / (Loss) Continuing Operations		 -108 -162 -116 -133 -156 -195 -213 -248 -305 -365 -454
Total Pre-Tax Income 		-112 -161 -116 -133 -156 -195 -213 -248 -305 -365 -454
Total Operating Income		 -123 -180 -141 -157 -176 -216 -241 -265 -315 -362 -445
Total Gross Profit		 0.00 0.74 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 0.74 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 123 181 141 157 176 216 241 265 315 362 445
Selling, General & Admin Expense		 16 32 23 22 24 29 35 41 53 67 101
Research & Development Expense		 108 148 118 135 152 188 206 224 263 295 344
Total Other Income / (Expense), net		 11 19 25 23 19 21 27 17 10 -3.27 -8.59
Interest Expense		 - - - -0.02 - - 0.00 0.90 11 - 12
Interest & Investment Income		 11 19 24 21 20 21 25 22 22 21 20
Other Income / (Expense), net		 0.00 -0.19 1.10 1.91 0.28 -5.83 2.43 -4.58 -0.59 -13 -16
Basic Earnings per Share		 ($0.99) ($1.23) ($0.70) ($0.81) ($0.94) ($1.13) ($1.13) ($1.31) ($1.61) ($1.90) ($2.29)
Weighted Average Basic Shares Outstanding		 109.23M 113.15M 164.73M 165.14M 166.84M 167.74M 188.15M 188.58M 189.23M 190.13M 198.10M
Diluted Earnings per Share		 ($0.99) ($1.23) ($0.70) ($0.81) ($0.94) ($1.13) ($1.13) ($1.31) ($1.61) ($1.90) ($2.29)
Weighted Average Diluted Shares Outstanding		 109.23M 113.15M 164.73M 165.14M 166.84M 167.74M 188.15M 188.58M 189.23M 190.13M 198.10M
Weighted Average Basic & Diluted Shares Outstanding		 109.56M 164.69M 164.99M 167.04M 168.22M 185.91M 186.27M 186.93M 193.32M 198.17M 212.60M

Annual Cash Flow Statements for Revolution Medicines

This table details how cash moves in and out of Revolution Medicines' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 61 -53 88 4.88 53 536 -152 -158
Net Cash From Operating Activities		 1.21 -50 -100 -147 -224 -351 -557 -898
Net Cash From Continuing Operating Activities		 1.21 -50 -100 -147 -224 -351 -557 -898
Net Income / (Loss) Continuing Operations		 -42 -48 -108 -187 -249 -436 -600 -1,131
Consolidated Net Income / (Loss)		 -42 -48 -108 -187 -249 -436 -600 -1,131
Depreciation Expense		 1.57 2.27 2.61 3.08 3.97 5.04 6.56 7.78
Amortization Expense		 0.20 0.62 4.90 7.26 2.61 -18 -39 -19
Non-Cash Adjustments To Reconcile Net Income		 3.18 3.98 8.89 21 31 62 75 158
Changes in Operating Assets and Liabilities, net		 38 -8.83 -8.30 8.72 -13 37 0.41 87
Net Cash From Investing Activities		 -1.34 -102 -234 -142 -24 -343 -554 118
Net Cash From Continuing Investing Activities		 -1.34 -102 -234 -142 -24 -343 -554 118
Purchase of Property, Plant & Equipment		 -1.50 -2.59 -2.93 -6.53 -11 -7.73 -10 -16
Purchase of Investments		 0.00 -172 -544 -671 -613 -1,059 -2,137 -1,795
Sale and/or Maturity of Investments		 0.00 67 313 536 599 724 1,593 1,929
Net Cash From Financing Activities		 61 99 423 294 301 1,229 959 622
Net Cash From Continuing Financing Activities		 61 99 423 294 301 1,229 959 622
Issuance of Common Equity		 0.42 0.28 423 295 301 389 947 356
Other Financing Activities, net		 0.13 -1.65 0.00 -0.42 0.04 840 13 266

Quarterly Cash Flow Statements for Revolution Medicines

This table details how cash moves in and out of Revolution Medicines' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -22 338 -408 -13 -75 343 -210 69 -184 166 57
Net Cash From Operating Activities		 -100 -121 -161 -128 -130 -138 -194 -222 -207 -274 -354
Net Cash From Continuing Operating Activities		 -100 -126 -161 -128 -130 -138 -194 -222 -207 -274 -354
Net Income / (Loss) Continuing Operations		 -108 -162 -116 -133 -156 -195 -213 -248 -305 -365 -454
Consolidated Net Income / (Loss)		 -108 -162 -116 -133 -156 -195 -213 -248 -305 -365 -454
Depreciation Expense		 1.27 - 1.54 1.64 1.64 1.74 1.69 1.76 2.06 2.27 2.35
Amortization Expense		 -4.27 -7.12 -14 -9.75 -8.36 -7.17 -7.79 -5.70 -3.44 -2.12 -1.03
Non-Cash Adjustments To Reconcile Net Income		 14 26 15 18 22 19 23 34 43 58 115
Changes in Operating Assets and Liabilities, net		 -2.73 21 -47 -4.74 10 42 2.44 -4.30 56 32 -17
Net Cash From Investing Activities		 77 -380 -248 108 -21 -393 -16 34 25 75 173
Net Cash From Continuing Investing Activities		 77 -380 -248 108 -21 -393 -16 34 25 75 173
Purchase of Property, Plant & Equipment		 -2.54 -2.32 -3.17 -2.40 -3.52 -1.22 -3.27 -7.45 -3.35 -1.93 -1.54
Purchase of Investments		 -170 -520 -702 -375 -365 -695 -510 -529 -459 -296 -210
Sale and/or Maturity of Investments		 250 142 457 485 347 304 497 571 487 373 384
Net Cash From Financing Activities		 1.01 839 0.81 7.50 77 874 0.87 257 -1.59 366 239
Net Cash From Continuing Financing Activities		 1.01 839 0.81 7.50 77 874 0.87 257 -1.59 366 239
Issuance of Common Equity		 1.01 2.55 0.81 7.50 77 874 0.89 6.58 4.15 344 239
Other Financing Activities, net		 - - 0.00 - - - -0.02 250 -5.74 21 -0.20

Annual Balance Sheets for Revolution Medicines

This table presents Revolution Medicines' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 221 567 738 812 2,062 2,558 2,355
Total Current Assets		 134 454 590 660 1,879 2,328 2,075
Cash & Equivalents		 17 104 108 161 696 543 384
Short-Term Investments		 106 336 469 484 1,157 1,746 1,642
Accounts Receivable		 8.74 6.39 5.93 4.67 1.25 - 0.00
Prepaid Expenses		 2.49 6.99 6.79 11 25 38 49
Plant, Property, & Equipment, net		 7.15 8.90 12 19 23 24 33
Total Noncurrent Assets		 79 104 137 133 160 206 246
Goodwill		 15 15 15 15 15 15 15
Intangible Assets		 62 61 60 59 58 57 56
Other Noncurrent Operating Assets		 2.78 29 62 60 87 135 176
Total Liabilities & Shareholders' Equity		 221 567 738 812 2,062 2,558 2,355
Total Liabilities		 68 93 135 127 236 293 723
Total Current Liabilities		 43 47 60 62 144 164 290
Accounts Payable		 11 13 14 21 62 54 65
Accrued Expenses		 15 19 28 29 75 97 209
Other Current Liabilities		 0.00 3.67 6.21 6.77 7.37 13 16
Total Noncurrent Liabilities		 25 46 75 65 92 129 433
Noncurrent Deferred & Payable Income Tax Liabilities		 7.82 7.44 7.44 7.03 3.12 2.35 2.35
Other Noncurrent Operating Liabilities		 0.66 30 61 58 89 127 430
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -153 475 603 685 1,826 2,265 1,631
Total Preferred & Common Equity		 -153 475 603 685 1,826 2,265 1,631
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -153 475 603 685 1,826 2,265 1,631
Common Stock		 4.74 740 1,056 1,388 2,963 4,002 4,497
Retained Earnings		 -157 -266 -453 -701 -1,138 -1,738 -2,869
Accumulated Other Comprehensive Income / (Loss)		 0.07 0.12 -0.38 -1.78 0.54 1.32 3.24

Quarterly Balance Sheets for Revolution Medicines

This table presents Revolution Medicines' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 826 1,074 984 1,908 1,808 1,763 2,365 2,430 2,252 2,254
Total Current Assets		 675 922 824 1,729 1,625 1,579 2,135 2,176 1,977 1,968
Cash & Equivalents		 179 380 358 288 276 201 334 402 217 441
Short-Term Investments		 476 529 455 1,415 1,315 1,348 1,769 1,735 1,714 1,467
Accounts Receivable		 4.94 2.51 0.31 0.00 0.00 0.00 0.00 - - 0.00
Prepaid Expenses		 15 10 11 26 34 30 32 39 46 60
Plant, Property, & Equipment, net		 18 20 20 24 25 25 27 33 33 31
Total Noncurrent Assets		 133 132 139 155 158 159 204 220 225 254
Goodwill		 15 15 15 15 15 15 15 15 15 15
Intangible Assets		 59 58 58 57 57 57 56 56 56 56
Other Noncurrent Operating Assets		 59 59 67 83 87 88 133 149 154 184
Total Liabilities & Shareholders' Equity		 826 1,074 984 1,908 1,808 1,763 2,365 2,430 2,252 2,254
Total Liabilities		 144 143 147 183 190 197 287 564 655 754
Total Current Liabilities		 73 78 86 94 105 111 159 185 246 290
Accounts Payable		 24 30 30 32 29 24 48 57 75 81
Accrued Expenses		 32 43 50 53 68 78 98 115 154 192
Other Current Liabilities		 7.02 5.72 5.76 8.17 8.33 8.40 13 13 16 17
Total Noncurrent Liabilities		 71 65 61 89 84 86 129 380 409 464
Noncurrent Deferred & Payable Income Tax Liabilities		 7.15 7.03 3.16 3.12 3.12 3.12 2.35 2.35 2.35 2.35
Other Noncurrent Operating Liabilities		 59 58 58 86 81 83 126 377 407 462
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 681 931 837 1,725 1,619 1,566 2,078 1,865 1,597 1,500
Total Preferred & Common Equity		 681 931 837 1,725 1,619 1,566 2,078 1,865 1,597 1,500
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 681 931 837 1,725 1,619 1,566 2,078 1,865 1,597 1,500
Common Stock		 1,329 1,800 1,815 2,980 3,008 3,106 4,028 4,063 4,098 4,823
Retained Earnings		 -645 -868 -976 -1,254 -1,387 -1,543 -1,951 -2,199 -2,504 -3,323
Accumulated Other Comprehensive Income / (Loss)		 -2.42 -1.25 -0.87 -1.20 -1.86 3.81 1.71 1.30 3.12 -0.62

Annual Metrics And Ratios for Revolution Medicines

This table displays calculated financial ratios and metrics derived from Revolution Medicines' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 148.16% -14.10% -31.62% 20.38% -67.27% -100.00% 0.00%
EBITDA Growth		 0.00% -25.91% -101.42% -72.19% -41.66% -100.76% -43.44% -66.81%
EBIT Growth		 0.00% -27.49% -104.54% -69.85% -37.37% -88.70% -42.00% -73.07%
NOPAT Growth		 0.00% -34.20% -104.54% -69.84% -37.38% -88.63% -41.53% -71.48%
Net Income Growth		 0.00% -14.06% -126.92% -72.98% -32.93% -75.46% -37.52% -88.52%
EPS Growth		 0.00% -5.13% 91.00% -27.86% -19.84% -25.32% 7.25% -66.20%
Operating Cash Flow Growth		 0.00% -4,190.35% -101.68% -47.09% -52.47% -56.23% -59.01% -61.05%
Free Cash Flow Firm Growth		 0.00% 0.00% -20.67% -50.88% -58.73% -40.15% -77.11% 5.76%
Invested Capital Growth		 0.00% 0.00% 13.96% -24.82% 57.74% -166.50% 9.96% -1,536.78%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 2.47% 13.95% -52.98% -100.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -11.40% -3.11% -35.88% -6.09% -13.80%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -11.14% -1.84% -33.61% -6.46% -14.55%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -11.13% -1.84% -33.56% -5.56% -14.01%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -10.95% -0.10% -33.14% -5.83% -17.72%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -14.73% 4.64% -20.63% 2.72% -14.86%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -15.44% -10.70% -11.16% -20.14% -3.28% -17.85%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -12.12% -8.23% -7.90% -27.88%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -13.66% 52.41% -210.30% -243.23% -12.21%
Profitability Metrics		 - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00%
EBITDA Margin		 -201.77% -102.37% -240.06% -604.55% -711.42% -4,363.65% 0.00% 0.00%
Operating Margin		 -200.00% -108.15% -257.54% -639.70% -730.01% -4,207.12% 0.00% 0.00%
EBIT Margin		 -210.51% -108.15% -257.54% -639.74% -730.01% -4,208.75% 0.00% 0.00%
Profit (Net Income) Margin		 -207.24% -95.25% -251.63% -636.58% -702.95% -3,768.28% 0.00% 0.00%
Tax Burden Percent		 100.00% 91.60% 99.66% 100.00% 99.83% 99.20% 99.87% 100.00%
Interest Burden Percent		 98.44% 96.15% 98.04% 99.51% 96.46% 90.26% 86.82% 94.45%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -254.45% -243.24% -442.75% -549.87% -5,058.28% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -238.52% -232.36% -431.85% -538.76% -5,050.65% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 191.96% 208.76% 408.02% 511.25% 5,023.53% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -62.50% -34.49% -34.74% -38.63% -34.75% -29.33% -58.07%
Cash Return on Invested Capital (CROIC)		 0.00% -454.45% -256.30% -414.42% -594.68% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -24.54% -28.10% -28.81% -33.33% -33.92% 0.00% 0.00%
Return on Assets (ROA)		 0.00% -21.61% -27.45% -28.66% -32.09% -30.37% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 62.51% -17.71% -34.74% -38.63% -34.75% -29.33% -58.07%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 31.24% -22.79% -31.05% -36.30% -23.89% -26.49% 0.00%
Net Operating Profit after Tax (NOPAT)		 -28 -38 -77 -132 -181 -341 -483 -828
NOPAT Margin		 -140.00% -75.71% -180.28% -447.79% -511.01% -2,944.99% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -15.93% -10.89% -10.90% -11.11% -7.63% -5.67% -14.07%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -26.39% -18.67% -21.31% -50.74%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 46.67% 24.79% 49.85% 103.61% 114.71% 653.03% 0.00% 0.00%
R&D to Revenue		 253.33% 183.36% 307.68% 636.09% 715.30% 3,654.09% 0.00% 0.00%
Operating Expenses to Revenue		 300.00% 208.15% 357.54% 739.70% 830.01% 4,307.12% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -42 -54 -111 -188 -258 -487 -692 -1,198
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -41 -51 -103 -178 -252 -505 -725 -1,209
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 5.54 3.08 3.09 1.72 3.25 9.44
Price to Tangible Book Value (P/TBV)		 0.00 0.00 6.58 3.51 3.46 1.79 3.35 9.86
Price to Revenue (P/Rev)		 7.44 3.00 61.14 63.11 59.78 271.36 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 11.16 64.45 50.08 36.53 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 6.64 50.89 43.47 41.55 111.34 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -0.80 -0.90 -0.94 -0.95 -0.99 -1.01 -1.11
Leverage Ratio		 0.00 1.45 1.26 1.21 1.20 1.14 1.13 1.26
Compound Leverage Factor		 0.00 1.39 1.23 1.21 1.16 1.03 0.98 1.19
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 200.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -100.03% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.24 16.64 7.42 8.68 7.47 14.23 10.30
Noncontrolling Interest Sharing Ratio		 0.00% 200.03% 48.65% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 0.00 3.11 9.63 9.77 10.65 13.06 14.20 7.14
Quick Ratio		 0.00 3.05 9.48 9.66 10.48 12.89 13.97 6.97
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -68 -82 -123 -196 -274 -485 -457
Operating Cash Flow to CapEx		 80.92% -2,073.38% -3,411.66% -2,254.60% -2,074.71% -4,535.80% -5,407.80% -5,614.39%
Free Cash Flow to Firm to Interest Expense		 0.00 -638.31 -1,149.94 0.00 0.00 0.00 0.00 -18.88
Operating Cash Flow to Interest Expense		 10.46 -468.08 -1,409.35 0.00 0.00 0.00 0.00 -37.05
Operating Cash Flow Less CapEx to Interest Expense		 -2.47 -490.65 -1,450.66 0.00 0.00 0.00 0.00 -37.71
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.23 0.11 0.05 0.05 0.01 0.00 0.00
Accounts Receivable Turnover		 0.00 5.73 5.68 4.77 6.67 3.91 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 7.00 5.36 2.87 2.34 0.56 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 63.73 64.24 76.51 54.69 93.41 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 63.73 64.24 76.51 54.69 93.41 0.00 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 0.00 30 34 26 40 -27 -24 -394
Invested Capital Turnover		 0.00 3.36 1.35 0.99 1.08 1.72 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 30 4.16 -8.42 15 -67 2.67 -370
Enterprise Value (EV)		 0.00 332 2,187 1,278 1,470 1,289 5,069 13,372
Market Capitalization		 150 150 2,628 1,855 2,115 3,142 7,358 15,398
Book Value per Share		 $0.00 ($55.03) $7.15 $8.18 $7.72 $16.67 $13.47 $8.44
Tangible Book Value per Share		 $0.00 ($82.66) $6.01 $7.17 $6.89 $16.01 $13.04 $8.07
Total Capital		 0.00 153 475 603 685 1,826 2,265 1,631
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -123 -441 -577 -645 -1,853 -2,289 -2,026
Capital Expenditures (CapEx)		 1.50 2.39 2.93 6.53 11 7.73 10 16
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -32 -34 -48 -47 -118 -126 -241
Debt-free Net Working Capital (DFNWC)		 0.00 91 407 529 598 1,735 2,164 1,785
Net Working Capital (NWC)		 0.00 91 407 529 598 1,735 2,164 1,785
Net Nonoperating Expense (NNE)		 14 9.78 31 55 68 95 117 304
Net Nonoperating Obligations (NNO)		 0.00 -123 -441 -577 -645 -1,853 -2,289 -2,026
Total Depreciation and Amortization (D&A)		 1.76 2.89 7.51 10 6.58 -18 -33 -11
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -63.61% -78.62% -162.07% -132.11% -1,014.90% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 181.71% 946.76% 1,801.37% 1,690.79% 14,986.44% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 181.71% 946.76% 1,801.37% 1,690.79% 14,986.44% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($2.01) ($2.57) ($3.08) ($3.86) ($3.58) ($5.95)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 73.38M 74.19M 80.63M 113.15M 167.74M 190.13M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($2.01) ($2.57) ($3.08) ($3.86) ($3.58) ($5.95)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 73.38M 74.19M 80.63M 113.15M 167.74M 190.13M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($2.01) ($2.57) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 54.87M 72.81M 90.49M 164.69M 185.91M 198.17M
Normalized Net Operating Profit after Tax (NOPAT)		 -28 -38 -77 -132 -181 -341 -483 -828
Normalized NOPAT Margin		 -140.00% -75.71% -180.28% -447.79% -511.01% -2,944.99% 0.00% 0.00%
Pre Tax Income Margin		 -207.24% -103.99% -252.50% -636.58% -704.14% -3,798.71% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 -365.95 -510.57 -1,559.11 0.00 0.00 0.00 0.00 -49.43
NOPAT to Interest Expense		 -243.36 -357.40 -1,091.38 0.00 0.00 0.00 0.00 -34.16
EBIT Less CapEx to Interest Expense		 -378.87 -533.14 -1,600.42 0.00 0.00 0.00 0.00 -50.09
NOPAT Less CapEx to Interest Expense		 -256.29 -379.97 -1,132.69 0.00 0.00 0.00 0.00 -34.82
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Revolution Medicines

This table displays calculated financial ratios and metrics derived from Revolution Medicines' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 198,173,397.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 198,173,397.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -2.29
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% -94.62% -100.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -67.75% -225.38% -99.79% -45.54% -44.28% -21.51% -60.55% -67.79% -74.17% -64.41% -88.02%
EBIT Growth		 -61.04% -212.97% -85.96% -42.21% -42.34% -23.29% -70.53% -74.03% -80.05% -68.50% -93.38%
NOPAT Growth		 -61.04% -212.64% -87.42% -43.98% -42.57% -20.18% -70.92% -68.99% -79.42% -67.18% -84.92%
Net Income Growth		 -47.87% -205.18% -70.35% -35.54% -44.13% -20.45% -83.97% -85.98% -95.28% -87.54% -112.64%
EPS Growth		 -13.79% -115.79% 2.78% 11.96% 5.05% 8.13% -61.43% -61.73% -71.28% -68.14% -102.65%
Operating Cash Flow Growth		 -94.25% -95.12% -157.34% -90.95% -29.77% -14.70% -21.10% -73.02% -58.96% -98.31% -82.15%
Free Cash Flow Firm Growth		 -66.83% -7.18% -137.75% -255.57% -37.36% -161.24% -23.09% 183.20% 227.72% 176.03% 158.97%
Invested Capital Growth		 -8.12% -166.50% 2.72% 0.00% -30.66% 9.96% -211.85% -1,066.13% -2,189.13% -1,536.78% -1,564.29%
Revenue Q/Q Growth		 -100.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -12.85% -48.35% 18.04% -6.95% -11.87% -24.94% -7.41% -11.78% -16.11% -17.93% -22.84%
EBIT Q/Q Growth		 -13.28% -46.19% 22.35% -10.70% -13.39% -26.63% -7.29% -12.99% -17.29% -18.50% -23.14%
NOPAT Q/Q Growth		 -13.28% -46.03% 21.74% -11.21% -12.17% -23.10% -11.30% -9.95% -19.10% -14.70% -23.12%
Net Income Q/Q Growth		 -10.31% -48.97% 28.19% -14.85% -17.30% -24.49% -9.69% -16.11% -23.17% -19.56% -24.37%
EPS Q/Q Growth		 -7.61% -24.24% 43.09% -15.71% -16.05% -20.21% 0.00% -15.93% -22.90% -18.01% -20.53%
Operating Cash Flow Q/Q Growth		 -49.73% -19.97% -33.18% 20.18% -1.76% -6.04% -40.60% -14.05% 6.51% -32.28% -29.15%
Free Cash Flow Firm Q/Q Growth		 -117.11% 29.89% -68.16% -38.92% 16.13% -33.34% 20.77% 193.90% 28.75% -20.63% -38.55%
Invested Capital Q/Q Growth		 0.00% -210.30% 181.94% 28.30% -40.20% -243.23% -1.78% -1,008.27% -29.31% -12.21% -3.50%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% -25,241.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% -24,256.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% -24,281.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% -21,770.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 96.56% 100.21% 100.00% 100.00% 100.00% 99.61% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 91.12% 89.47% 83.00% 86.11% 89.09% 87.93% 89.55% 92.01% 96.63% 97.49% 98.46%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -29,163.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -29,161.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 29,004.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -159.42% 0.00% 0.00% 0.00% -29.33% -36.68% -46.61% -60.76% -58.07% -76.67%
Cash Return on Invested Capital (CROIC)		 -999.41% 0.00% -1,791.43% -3,189.47% -2,189.54% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -195.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% -175.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% -159.42% 0.00% 0.00% 0.00% -29.33% -36.68% -46.61% -60.76% -58.07% -76.67%
Return on Equity Simple (ROE_SIMPLE)		 -39.14% 0.00% -28.07% -32.07% -36.20% 0.00% -33.56% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -86 -126 -99 -110 -123 -151 -169 -185 -221 -253 -312
NOPAT Margin		 0.00% -16,979.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.02% -2.85% -1.33% -2.97% -2.82% -2.08% -2.36% -3.35% -4.83% -5.18% -7.09%
Return On Investment Capital (ROIC_SIMPLE)		 - -6.90% - - - -6.68% -8.11% -9.93% -13.82% -15.52% -20.78%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 4,345.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 20,010.92% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 24,356.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -123 -180 -140 -155 -175 -222 -238 -269 -316 -374 -461
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -126 -187 -152 -163 -182 -228 -244 -273 -317 -374 -460
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.61 1.72 2.05 3.96 4.84 3.25 3.16 3.67 5.47 9.44 12.85
Price to Tangible Book Value (P/TBV)		 3.95 1.79 2.14 4.14 5.07 3.35 3.28 3.82 5.72 9.86 13.48
Price to Revenue (P/Rev)		 122.69 271.36 773.38 8,629.54 10,209.19 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 91.03 0.00 83.36 171.06 358.18 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 89.67 111.34 400.29 6,485.71 8,120.94 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.97 -0.99 -0.98 -0.98 -0.98 -1.01 -1.00 -1.07 -1.11 -1.11 -1.12
Leverage Ratio		 1.19 1.14 1.12 1.12 1.14 1.13 1.12 1.22 1.27 1.26 1.29
Compound Leverage Factor		 1.09 1.02 0.93 0.96 1.02 0.99 1.01 1.12 1.23 1.23 1.27
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 11.48 7.96 11.45 19.92 22.55 14.84 13.25 6.64 6.90 11.45 13.49
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.64 13.06 18.45 15.42 14.24 14.20 13.46 11.79 8.05 7.14 6.80
Quick Ratio		 9.51 12.89 18.18 15.10 13.98 13.97 13.26 11.58 7.86 6.97 6.59
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -84 -59 -99 -138 -116 -154 -122 115 148 117 72
Operating Cash Flow to CapEx		 -3,964.38% -5,203.41% -5,069.78% -5,342.52% -3,705.09% -11,316.69% -5,953.31% -2,976.60% -6,190.24% -14,246.13% -23,027.63%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 127.51 12.91 0.00 5.90
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -246.67 -18.14 0.00 -29.04
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -254.96 -18.43 0.00 -29.16
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 9.38 3.91 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.28 0.56 0.21 0.03 0.03 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 38.89 93.41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 38.89 93.41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 24 -27 22 28 17 -24 -25 -272 -351 -394 -408
Invested Capital Turnover		 0.97 1.72 0.21 0.05 0.04 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -2.14 -67 0.58 28 -7.44 2.67 -46 -300 -368 -370 -384
Enterprise Value (EV)		 2,209 1,289 1,828 4,812 6,026 5,069 4,471 4,716 6,798 13,372 17,364
Market Capitalization		 3,022 3,142 3,531 6,403 7,575 7,358 6,574 6,853 8,730 15,398 19,272
Book Value per Share		 $7.67 $16.67 $10.47 $9.81 $9.38 $13.47 $11.18 $10.01 $8.54 $8.44 $7.57
Tangible Book Value per Share		 $7.01 $16.01 $10.04 $9.38 $8.95 $13.04 $10.80 $9.63 $8.17 $8.07 $7.21
Total Capital		 837 1,826 1,725 1,619 1,566 2,265 2,078 1,865 1,597 1,631 1,500
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -813 -1,853 -1,704 -1,591 -1,549 -2,289 -2,103 -2,137 -1,932 -2,026 -1,908
Capital Expenditures (CapEx)		 2.54 2.32 3.17 2.40 3.52 1.22 3.27 7.45 3.35 1.93 1.54
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -74 -118 -68 -71 -81 -126 -127 -145 -200 -241 -230
Debt-free Net Working Capital (DFNWC)		 739 1,735 1,635 1,519 1,468 2,164 1,976 1,992 1,732 1,785 1,678
Net Working Capital (NWC)		 739 1,735 1,635 1,519 1,468 2,164 1,976 1,992 1,732 1,785 1,678
Net Nonoperating Expense (NNE)		 22 36 17 24 33 43 45 62 85 112 142
Net Nonoperating Obligations (NNO)		 -813 -1,853 -1,704 -1,591 -1,549 -2,289 -2,103 -2,137 -1,948 -2,026 -1,908
Total Depreciation and Amortization (D&A)		 -3.00 -7.12 -12 -8.11 -6.72 -5.44 -6.10 -3.94 -1.38 0.15 1.31
Debt-free, Cash-free Net Working Capital to Revenue		 -301.54% -1,014.90% -1,490.60% -9,611.46% -10,944.07% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 3,000.11% 14,986.44% 35,818.64% 204,770.62% 197,880.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 3,000.11% 14,986.44% 35,818.64% 204,770.62% 197,880.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.99) ($1.23) ($0.70) ($0.81) ($0.94) ($1.13) ($1.13) ($1.31) ($1.61) ($1.90) ($2.29)
Adjusted Weighted Average Basic Shares Outstanding		 109.23M 113.15M 164.73M 165.14M 166.84M 167.74M 188.15M 188.58M 189.23M 190.13M 198.10M
Adjusted Diluted Earnings per Share		 ($0.99) ($1.23) ($0.70) ($0.81) ($0.94) ($1.13) ($1.13) ($1.31) ($1.61) ($1.90) ($2.29)
Adjusted Weighted Average Diluted Shares Outstanding		 109.23M 113.15M 164.73M 165.14M 166.84M 167.74M 188.15M 188.58M 189.23M 190.13M 198.10M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 109.56M 164.69M 164.99M 167.04M 168.22M 185.91M 186.27M 186.93M 193.32M 198.17M 212.60M
Normalized Net Operating Profit after Tax (NOPAT)		 -86 -126 -99 -110 -123 -151 -169 -185 -221 -253 -312
Normalized NOPAT Margin		 0.00% -16,979.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% -21,724.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -299.55 -27.64 0.00 -37.79
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -206.12 -19.31 0.00 -25.55
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -307.83 -27.93 0.00 -37.91
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -214.40 -19.60 0.00 -25.68
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Here are the key financial trends for Revolution Medicines (RVMD) based on the last four years of quarterly statements. The data show a pre-revenue biotech with substantial R&D spend, financed largely through equity offerings and some portfolio liquidations.

  • Financing-driven liquidity: Financing activities provided sizable liquidity through common-equity issuances, including a substantial equity raise of about $344.3 million in Q4 2024 and a net financing inflow of about $365.7 million in Q4 2025.
  • Investing inflows from portfolio activity: Investing activities generated large cash inflows in several quarters from the sale/maturity of investments (Q2 2025 roughly $571.0 million; Q3 2025 roughly $487.2 million; Q4 2025 roughly $373.3 million).
  • Q4 2025 investing cash flow: Net cash from investing activities in Q4 2025 was about $74.9 million, contributing to overall liquidity alongside ongoing financing inflows.
  • Revenue trend: Total revenue has been zero in recent periods, indicating the company remains in a pre-product-revenue phase without demonstrated product sales.
  • Recurring net losses: Net income in Q4 2025 was -$364.892 million, continuing a pattern of annual losses as operating expenses exceed revenue.
  • R&D spend rising: Research & development expense climbed to about $294.943 million in Q4 2025, up from about $187.520 million in Q4 2024, indicating heightened clinical development activity.
  • SG&A expense growth: Selling, general & administrative expense rose to about $66.683 million in Q4 2025, up from about $28.790 million in Q4 2024, contributing to higher operating costs.
  • Operating cash burn persists: Net cash from continuing operating activities was -$274.238 million in Q4 2025, with negative cash flow from operations in multiple quarters in the period observed.
  • Persistent accumulated deficit: Retained earnings reflect a substantial accumulated deficit, indicating ongoing capital burn and the need for continued outside funding to support operations.
  • Dilution pressures from equity issuance: Shares outstanding metrics show dilution, with weighted-average basic shares outstanding at about 190.1 million in Q4 2025, higher than prior quarters (roughly 188–189 million in earlier periods).
05/11/26 05:05 PM ETAI Generated. May Contain Errors.

Revolution Medicines Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Revolution Medicines' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Revolution Medicines' net income appears to be on an upward trend, with a most recent value of -$1.13 billion in 2025, rising from -$41.79 million in 2018. The previous period was -$600.09 million in 2024. View Revolution Medicines' forecast to see where analysts expect Revolution Medicines to go next.

Revolution Medicines' total operating income in 2025 was -$1.18 billion, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $1.18 billion

Over the last 7 years, Revolution Medicines' total revenue changed from $20.17 million in 2018 to $0.00 in 2025, a change of -100.0%.

Revolution Medicines' total liabilities were at $723.21 million at the end of 2025, a 146.7% increase from 2024, and a 963.6% increase since 2019.

In the past 6 years, Revolution Medicines' cash and equivalents has ranged from $16.66 million in 2019 to $696.15 million in 2023, and is currently $383.75 million as of their latest financial filing in 2025.

Over the last 7 years, Revolution Medicines' book value per share changed from 0.00 in 2018 to 8.44 in 2025, a change of 843.8%.


Related Companies

Financial statements for NASDAQ:RVMD last updated on 5/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon’s AI supercomputer just went live. Here’s my #1 stock.
Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...
InvestorPlace | Sponsoredtc pixel